Holtappels Rafaela, Simon Christian O, Munks Michael W, Thomas Doris, Deegen Petra, Kühnapfel Birgit, Däubner Torsten, Emde Simone F, Podlech Jürgen, Grzimek Natascha K A, Oehrlein-Karpi Silke A, Hill Ann B, Reddehase Matthias J
Institute for Virology, Johannes Gutenberg University, Hochhaus am Augustusplatz, 55131 Mainz, Germany.
J Virol. 2008 Jun;82(12):5781-96. doi: 10.1128/JVI.00155-08. Epub 2008 Mar 26.
Cytomegalovirus (CMV) infection continues to be a complication in recipients of hematopoietic stem cell transplantation (HSCT). Preexisting donor immunity is recognized as a favorable prognostic factor for the reconstitution of protective antiviral immunity mediated primarily by CD8 T cells. Furthermore, adoptive transfer of CMV-specific memory CD8 T (CD8-T(M)) cells is a therapeutic option for preventing CMV disease in HSCT recipients. Given the different CMV infection histories of donor and recipient, a problem may arise from an antigenic mismatch between the CMV variant that has primed donor immunity and the CMV variant acquired by the recipient. Here, we have used the BALB/c mouse model of CMV infection in the immunocompromised host to evaluate the importance of donor-recipient CMV matching in immundominant epitopes (IDEs). For this, we generated the murine CMV (mCMV) recombinant virus mCMV-DeltaIDE, in which the two memory repertoire IDEs, the IE1-derived peptide 168-YPHFMPTNL-176 presented by the major histocompatibility complex class I (MHC-I) molecule L(d) and the m164-derived peptide 257-AGPPRYSRI-265 presented by the MHC-I molecule D(d), are both functionally deleted. Upon adoptive transfer, polyclonal donor CD8-T(M) cells primed by mCMV-DeltaIDE and the corresponding revertant virus mCMV-revDeltaIDE controlled infection of immunocompromised recipients with comparable efficacy and regardless of whether or not IDEs were presented in the recipients. Importantly, CD8-T(M) cells primed under conditions of immunodomination by IDEs protected recipients in which IDEs were absent. This shows that protection does not depend on compensatory expansion of non-IDE-specific CD8-T(M) cells liberated from immunodomination by the deletion of IDEs. We conclude that protection is, rather, based on the collective antiviral potential of non-IDEs independent of the presence or absence of IDE-mediated immunodomination.
巨细胞病毒(CMV)感染仍是造血干细胞移植(HSCT)受者的一种并发症。预先存在的供体免疫力被认为是主要由CD8 T细胞介导的保护性抗病毒免疫重建的有利预后因素。此外,过继转移CMV特异性记忆CD8 T(CD8-T(M))细胞是预防HSCT受者发生CMV疾病的一种治疗选择。鉴于供体和受者不同的CMV感染史,引发供体免疫力的CMV变异体与受者获得的CMV变异体之间的抗原错配可能会引发问题。在此,我们使用免疫受损宿主中的BALB/c小鼠CMV感染模型来评估供体-受体CMV在免疫显性表位(IDE)匹配中的重要性。为此,我们构建了鼠巨细胞病毒(mCMV)重组病毒mCMV-DeltaIDE,其中两个记忆库IDE,即由主要组织相容性复合体I类(MHC-I)分子L(d)呈递的IE1衍生肽168-YPHFMPTNL-176和由MHC-I分子D(d)呈递的m164衍生肽257-AGPPRYSRI-265,在功能上均被删除。过继转移后,由mCMV-DeltaIDE和相应的回复病毒mCMV-revDeltaIDE引发的多克隆供体CD8-T(M)细胞以相当的效力控制了免疫受损受者的感染,且无论受者中是否存在IDE。重要的是,在IDE免疫显性条件下引发的CD8-T(M)细胞保护了不存在IDE的受者。这表明保护并不依赖于因IDE缺失而从免疫显性中释放出来的非IDE特异性CD8-T(M)细胞的代偿性扩增。我们得出结论,保护更确切地说是基于非IDE的集体抗病毒潜力,而与IDE介导的免疫显性的存在与否无关。